Progression-free survival as surrogate end point for overall survival in clinical trials of HER2-targeted agents in HER2-positive metastatic breast cancer† - Annals of Oncology
Endpoints Used in Clinical Trials Endpoint Definition Overall survival... | Download Table
Disease-Free Survival As a Clinical Trial Endpoint: Does It Matter, and to Whom?
図10 Overall survival (primary endpoint)
Survival in oncology reimbursement decision-making | CMAR
Progression-free survival is a robust surrogate endpoint of overall survival in immunotherapy trials of hepatocellular carcinoma - Digestive and Liver Disease
Intermediate clinical endpoints: A bridge between progression‐free survival and overall survival in ovarian cancer trials - Matulonis - 2015 - Cancer - Wiley Online Library
JAMA Oncology on Twitter: "Radiographic progression-free survival in PREVAIL trial of #enzalutamide vs placebo for met castration-resistant #ProstateCancer is reliable & clinically meaningful endpoint highly assoc'd w overall survival https://t.co ...
Time to next treatment or death as a candidate surrogate endpoint for overall survival in advanced melanoma patients treated with immune checkpoint inhibitors: an insight from the phase III CheckMate 067 trial -
Figure: QUAZAR AML-001 primary endpoint: overall survival from... | Download Scientific Diagram
Kaplan-Meier estimates of (a) the primary endpoint of progression free... | Download Scientific Diagram
Surrogate Endpoint | Definitive Healthcare
Surrogate endpoints for overall survival in randomised controlled trials of localised osteosarcoma: A meta-analytic evaluation | Scientific Reports
Cumulative overall survival (OS) and progression-free survival (PFS)... | Download Scientific Diagram
ADMIRAL Trial: XOSPATA® (gilteritinib) Overall Survival
Disease-free and overall survival at 3.5 years for neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin and cyclophosphamide, for women with HER2 negative early breast cancer: ARTemis Trial - Annals of
Progression-free survival as a surrogate endpoint in advanced neuroendocrine neoplasms in: Endocrine-Related Cancer Volume 24 Issue 9 (2017)
Disease-Free Survival As a Clinical Trial Endpoint: Does It Matter, and to Whom?
ADMIRAL Trial: XOSPATA® (gilteritinib) Overall Survival
Clinical Trial Endpoints for Oncology Studies
Progression‑free survival of first‑line treatment with molecular‑targeted therapy may be a meaningful intermediate endpoint for overall survival in patients with metastatic renal cell carcinoma
Efficacy endpoints in Oncology
Merck Announces KEYTRUDA® (pembrolizumab) Met Primary Endpoint of Overall Survival (OS) in Patients with Advanced Hepatocellular Carcinoma Previously Treated with Sorafenib | Business Wire
Are progression-free and disease-free survival the new gold standard for cancer trials? | Cancer World Archive
Surrogate endpoints for overall survival in digestive oncology trials: which candidates? A questionnaires survey among clinicians and methodologists | BMC Cancer | Full Text
Progression-free survival as a surrogate for overall survival in oncology trials: a methodological systematic review | British Journal of Cancer
